PERSKY MARLA sold $91K of XERS
PERSKY MARLA sold 15,500 shares of Xeris Biopharma Holdings, Inc. (XERS) at $5.90 on 2026-06-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The market may briefly reprice on perceived insider sentiment, but 10b5-1 plans typically dampen interpretability as a forward-looking signal.
Market read
Useful for sentiment/positioning checks, but not a standalone fundamental catalyst.
What to watch
The filing does not indicate whether other insiders/funds are buying or whether there are concurrent corporate catalysts; without those, the trading signal is weak.
Background
SEC Form 4 reports insider transactions; this one is an open-market sale by a director, explicitly under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Director Marla Persky sold 15,500 Xeris Biopharma shares in an open-market transaction disclosed via SEC Form 4.
Likely limited/short-lived reaction; more relevant for monitoring than for a standalone trade catalyst.
The filing is an ownership-change disclosure with a stated pre-arranged 10b5-1 plan, which reduces the signal strength versus discretionary selling.
Market effects
Minimal—this is company-specific insider activity with no stated operational/regulatory catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect routine liquidity rather than bearish fundamentals.
Key entities
- issuerXeris Biopharma Holdings, Inc.
Subject of the insider transaction disclosure (SEC Form 4) involving director Marla Persky.
- insiderPERSKY MARLA
Director who sold 15,500 shares at $5.8989/share; holdings after sale: 126,500 shares.
